Pharsight

Drugs that contain Tranexamic Acid

1. Lysteda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8022106 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(9 months from now)

US8273795 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(9 months from now)

US8487005 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(9 months from now)

US8791160 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(9 months from now)

US8957113 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(9 months from now)

US8809394 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(9 months from now)

US9060939 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(9 months from now)

US7947739 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(9 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Nov 13, 2012

Market Authorisation Date: 13 November, 2009

Treatment: Treatment of cyclic heavy menstrual bleeding

Dosage: TABLET;ORAL

How can I launch a generic of LYSTEDA before it's drug patent expiration?
More Information on Dosage

LYSTEDA family patents

Family Patents